{"acute myeloid leukaemia": 2.13, "adenocarcinoma of colon": 25.42, "age-related macular degeneration": 24.88, "anaemia": 3.24, "aphonia": 4.18, "ascites": 4.46, "bacteraemia": 4.03, "blindness": 4.41, "blindness transient": 3.7, "blood albumin decreased": 3.9, "blood pressure diastolic increased": 9.89, "body temperature decreased": 4.02, "bone marrow disorder": 10.69, "bone marrow failure": 2.44, "candida infection": 2.27, "carcinoembryonic antigen increased": 15.96, "cardiotoxicity": 5.57, "colon cancer metastatic": 38.74, "colorectal cancer metastatic": 121.47, "dermatitis acneiform": 5.31, "diabetic foot": 12.33, "diabetic retinal oedema": 100.36, "diabetic retinopathy": 8.82, "diarrhoea": 2.64, "disease progression": 16.93, "disease recurrence": 2.2, "disseminated intravascular coagulation": 2.3, "drug resistance": 4.17, "dry throat": 4.23, "eastern cooperative oncology group performance status worsened": 30.38, "ejection fraction decreased": 3.35, "embolism": 5.02, "enteritis": 6.09, "epistaxis": 4.16, "eye discharge": 23.49, "eye disorder": 2.2, "eye haemorrhage": 9.73, "eye irritation": 2.44, "eye pruritus": 6.52, "febrile neutropenia": 8.1, "fournier's gangrene": 5.93, "gastrointestinal disorder": 2.76, "gastrointestinal perforation": 19.41, "gastrointestinal toxicity": 28.6, "gene mutation": 12.36, "granulocyte count decreased": 8.16, "haematocrit decreased": 2.32, "haematotoxicity": 26.86, "haemoglobin decreased": 2.37, "haemorrhage": 3.13, "hepatic steatosis": 2.55, "hepatitis b reactivation": 9.8, "hiccups": 5.39, "hyperbilirubinaemia": 2.6, "hypertension": 4.78, "hypomagnesaemia": 5.74, "ileus": 6.03, "incoherent": 4.58, "increased insulin requirement": 46.56, "interstitial lung disease": 2.11, "intestinal obstruction": 3.37, "intestinal perforation": 12.08, "large intestine perforation": 22.86, "left ventricular dysfunction": 8.51, "leukopenia": 5.11, "lymphocyte count decreased": 3.5, "macular oedema": 41.48, "magnetic resoce imaging head abnormal": 18.94, "maligt neoplasm progression": 7.43, "metastases to bone": 6.54, "metastases to central nervous system": 6.66, "metastases to liver": 17.06, "metastases to lung": 17.93, "metastases to lymph nodes": 11.92, "metastases to peritoneum": 21.85, "metastases to pleura": 26.25, "mucosal inflammation": 9.46, "myelodysplastic syndrome": 2.96, "myelosuppression": 22.99, "neoplasm progression": 12.57, "nephrotic syndrome": 5.74, "nerve injury": 2.14, "neuropathy peripheral": 10.64, "neurotoxicity": 15.5, "neutropenia": 9.67, "neutrophil count decreased": 12.98, "non-small cell lung cancer": 6.39, "ocular discomfort": 2.41, "osteonecrosis of jaw": 4.5, "ovarian cancer": 2.8, "palmar-plantar erythrodysaesthesia syndrome": 9.6, "paronychia": 9.47, "performance status decreased": 2.64, "peripheral sensory neuropathy": 8.26, "peritonitis": 3.53, "pharyngeal oedema": 2.5, "photopsia": 2.84, "platelet count decreased": 4.61, "pneumocystis jirovecii pneumonia": 3.25, "pneumonitis": 2.45, "polyneuropathy": 2.4, "poor peripheral circulation": 9.45, "portal hypertension": 8.89, "portal vein thrombosis": 7.05, "posterior reversible encephalopathy syndrome": 15.76, "product use issue": 3.38, "protein urine present": 5.64, "proteinuria": 17.18, "pulmonary toxicity": 4.37, "rectal haemorrhage": 2.05, "red blood cell count decreased": 2.24, "scleral thinning": 195.06, "second primary maligcy": 3.2, "skin toxicity": 17.56, "small intestinal obstruction": 5.26, "small intestinal perforation": 14.36, "splenomegaly": 2.05, "stomatitis": 3.81, "subretinal fluid": 23.16, "suture rupture": 98.07, "therapeutic product effect incomplete": 2.58, "therapy partial responder": 14.53, "thrombocytopenia": 4.68, "thrombotic microangiopathy": 6.61, "toxicity to various agents": 2.03, "treatment failure": 3.08, "tumour lysis syndrome": 3.08, "tumour necrosis": 89.28, "uveitis": 2.19, "visual acuity reduced": 3.05, "vitreous floaters": 3.12, "vitreous haemorrhage": 12.32, "white blood cell count decreased": 8.01, "wound dehiscence": 44.4, "wound infection": 7.25}